Plasma cells are found throughout the body, but their primary long-term home is the bone marrow. They also reside in lymph nodes, the spleen, and the mucosal lining of the gut and respiratory tract. Where a plasma cell ends up depends largely on whether it’s a short-lived cell responding to a recent infection or a long-lived cell settling into a permanent survival niche.
Bone Marrow: The Main Reservoir
The bone marrow houses the vast majority of the body’s long-lived plasma cells. In a healthy adult, plasma cells make up less than 5% of all bone marrow cells. That small percentage is deceptive, though, because these cells are antibody factories. Each one can pump out thousands of antibody molecules per second, and some survive in the marrow for months to years, maintaining immunity against infections you encountered long ago.
Plasma cells don’t survive in the bone marrow by accident. They depend on a specialized support system, sometimes called a survival niche, made up of stromal cells, certain immune cells, and chemical signals. Stromal cells in the marrow produce a signaling molecule (CXCL12) that acts like a homing beacon, pulling newly formed plasma cells out of the bloodstream and into the marrow. Once there, the plasma cells receive continuous survival signals from their neighbors. Without those signals, they die. This is why plasma cells aren’t intrinsically long-lived; their longevity comes from the environment around them.
After an immunization or infection, roughly 95% of the antigen-specific plasma cells that persist long-term end up in the bone marrow, with fewer than 5% remaining in the spleen. That makes the marrow the single most important tissue for sustained antibody production.
Lymph Nodes
Plasma cells are generated inside lymph nodes when B cells encounter a pathogen or vaccine antigen. The specific zone where they concentrate is the medullary cords, the inner tissue strands near the center of the node. These cords contain plasma cells alongside B cells and macrophages. Freshly activated B cells in the outer regions of a lymph node mature into antibody-secreting plasma cells and migrate inward to this location.
Most plasma cells born in lymph nodes are short-lived. They produce a burst of antibodies during the early phase of an immune response, then die within days to weeks. A smaller fraction exits the lymph node and migrates through the blood to the bone marrow, where it can settle into a long-term survival niche.
The Spleen
In the spleen, plasma cells are found primarily in the red pulp, the region responsible for filtering blood. B cells initially activate in the spleen’s white pulp (the immune-surveillance zone), then mature into plasma cells and migrate outward into the red pulp. The spleen provides some survival niches for long-lived plasma cells, but far fewer than the bone marrow. Studies in mice show that the splenic plasma cell population is roughly 60% short-lived, rapidly dividing plasmablasts, with a smaller stable population of mature, long-lived cells.
Mucosal Surfaces: Gut and Airways
The lining of the gastrointestinal and respiratory tracts contains large numbers of plasma cells, particularly ones that specialize in producing IgA, the antibody class that dominates in mucus and other secretions. These cells reside in mucosa-associated lymphoid tissue (MALT), a network of immune tissue embedded in the gut wall, tonsils, and bronchial lining.
Chronic exposure to bacteria and food antigens in the gut drives ongoing plasma cell production at these sites. The gut alone contains more antibody-producing cells than any other organ, making it a major but often overlooked location for plasma cells. Their job is frontline defense: neutralizing pathogens before they can breach the mucosal barrier.
How Plasma Cells Travel to Their Final Location
Plasma cells don’t start out where they end up. They begin as B cells that get activated in a lymph node, spleen, or mucosal tissue. After activation, they transition through a short-lived stage called a plasmablast, during which they’re still dividing and can travel through the bloodstream. Chemical signals guide them to their destination. The most important of these is the CXCL12-CXCR4 axis: bone marrow stromal cells release CXCL12, and plasma cells carrying the matching receptor (CXCR4) follow the signal like a trail of breadcrumbs into the marrow.
Once a plasma cell reaches a survival niche and receives the right combination of support signals, it stops dividing, settles in, and begins producing antibodies at a steady rate. Cells that fail to find a niche simply die, which is why the bone marrow’s limited number of survival spots creates a kind of competition. New plasma cells generated by a fresh infection can displace older residents, gradually reshaping your antibody repertoire over a lifetime.
Plasma Cells in Unexpected Places
In healthy tissue, plasma cells are largely confined to the locations above. But in chronic inflammation and autoimmune disease, plasma cells can show up in places they don’t normally belong. Inflamed joints in rheumatoid arthritis, salivary glands in Sjögren’s syndrome, and even the central nervous system in multiple sclerosis can develop structures called ectopic lymphoid structures. These are essentially makeshift immune outposts that form at sites of ongoing tissue damage, and they’re capable of generating and sustaining plasma cells locally.
In lupus, inflamed kidneys can create additional survival niches for long-lived plasma cells, contributing to persistent autoantibody production that’s difficult to shut down with conventional immune-suppressing treatments. These ectopic plasma cells are one reason autoimmune diseases can be so stubborn to treat: the antibody-producing cells aren’t just in the bone marrow where therapies might reach them, but embedded in the very tissues being attacked.
Why the Numbers Matter Clinically
Because plasma cells normally make up less than 5% of bone marrow cells, an elevated percentage is a red flag. A marrow sample showing 10% or more clonal plasma cells (meaning genetically identical, abnormal copies) meets one of the key criteria for diagnosing multiple myeloma, a cancer of plasma cells. Between the normal range and that 10% threshold sits a precursor condition called monoclonal gammopathy of undetermined significance (MGUS), where clonal plasma cells are present but haven’t yet caused organ damage. A smoldering stage, with 10 to 60% clonal plasma cells but no symptoms, sits between MGUS and active myeloma.
These thresholds help explain why bone marrow biopsies are central to diagnosing plasma cell disorders. The percentage of plasma cells, combined with blood tests and imaging, tells clinicians whether the cells are behaving normally or have crossed into dangerous territory.